Based on the X4 PHARMACEUTIC. DL-001 stock forecast from 0 analysts, the average analyst target price for X4 PHARMACEUTIC. DL-001 is not available over the next 12 months. X4 PHARMACEUTIC. DL-001’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of X4 PHARMACEUTIC. DL-001 is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, X4 PHARMACEUTIC. DL-001’s stock price was EUR 0.58. X4 PHARMACEUTIC. DL-001’s stock price has changed by -11.89% over the past week, +81.08% over the past month and -13.08% over the last year.
No recent analyst target price found for X4 PHARMACEUTIC. DL-001
No recent average analyst rating found for X4 PHARMACEUTIC. DL-001
Company Overview X4 PHARMACEUTIC. DL-001
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts. Read Less
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine ...Read More
Frequently Asked Questions About X4 PHARMACEUTIC. DL-001 (48Q:F) Stock
Stock Target Advisor's fundamental analysis for X4 PHARMACEUTIC. DL-001's stock is Slightly Bearish.
Unfortunately we do not have enough data on 48Q:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 48Q:F's stock to indicate what its average analyst target is.
48Q:F stock's Price/Earning ratio is 3.75.
Our analysis grades 48Q:F stock's Price / Earning ratio at B-. This means that 48Q:F stock's Price/Earning ratio is above 18.99999999999999% of the stocks in the Biotechnology sector in the F exchange.
Based on this 48Q:F may be undervalued for its sector.
The last closing price of 48Q:F's stock was EUR 0.58.
The most recent market capitalization for 48Q:F is EUR 0.10B.
Unfortunately we do not have enough analyst data on 48Q:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains X4 PHARMACEUTIC. DL-001's stock.
As per our most recent records X4 PHARMACEUTIC. DL-001 has 127 Employees.
X4 PHARMACEUTIC. DL-001's registered address is 61 North Beacon Street, Boston, MA, United States, 02134.
You can get more information about it from X4 PHARMACEUTIC. DL-001's website at https://www.x4pharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About X4 PHARMACEUTIC. DL-001 (48Q:F) Stock
Stock Target Advisor's fundamental analysis for X4 PHARMACEUTIC. DL-001's stock is Slightly Bearish.
Unfortunately we do not have enough data on 48Q:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 48Q:F's stock to indicate what its average analyst target is.
48Q:F stock's Price/Earning ratio is 3.75.
Our analysis grades 48Q:F stock's Price / Earning ratio at B-. This means that 48Q:F stock's Price/Earning ratio is above 18.99999999999999% of the stocks in the Biotechnology sector in the F exchange.
Based on this 48Q:F may be undervalued for its sector.
The last closing price of 48Q:F's stock was EUR 0.58.
The most recent market capitalization for 48Q:F is EUR 0.10B.
Unfortunately we do not have enough analyst data on 48Q:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains X4 PHARMACEUTIC. DL-001's stock.
As per our most recent records X4 PHARMACEUTIC. DL-001 has 127 Employees.
X4 PHARMACEUTIC. DL-001's registered address is 61 North Beacon Street, Boston, MA, United States, 02134.
You can get more information about it from X4 PHARMACEUTIC. DL-001's website at https://www.x4pharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 48Q:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
